Ken Griffin Alx Oncology Holdings Inc Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Alx Oncology Holdings Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 34,800 shares of ALXO stock, worth $53,244. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,800
Previous 9,100
282.42%
Holding current value
$53,244
Previous $101,000
106.93%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding ALXO
# of Institutions
116Shares Held
41MCall Options Held
518KPut Options Held
142K-
Ven Bio Partners LLC San Francisco, CA9.7MShares$14.8 Million33.06% of portfolio
-
Vivo Capital, LLC Palo Alto, CA4.22MShares$6.46 Million3.76% of portfolio
-
Redmile Group, LLC San Francisco, CA4.04MShares$6.18 Million1.59% of portfolio
-
Vestal Point Capital, LP New York, NY3.6MShares$5.51 Million1.62% of portfolio
-
Black Rock Inc. New York, NY2.69MShares$4.11 Million0.0% of portfolio
About ALX ONCOLOGY HOLDINGS INC
- Ticker ALXO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,747,100
- Market Cap $62.3M
- Description
- ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...